Prasco Laboratories has entered an agreement with Sunovion Pharmaceuticals Inc. to distribute an authorized generic version of Xopenex Inhalation Solution, a respiratory medication.


Prasco Laboratories, Xopenex Inhalation Solution, Sunovion Pharmaceuticals, authorized generic, Xopenex authorized generic, Christopher Arington, respiratory medication, bronchospasm, narrowing of the airways










































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Prasco to release Xopenex authorized generic

August 20th, 2012

CINCINNATI – Prasco Laboratories has entered an agreement with Sunovion Pharmaceuticals Inc. to distribute an authorized generic version of Xopenex Inhalation Solution, a respiratory medication.

Prasco said Monday that its Xopenex authorized generic product will be sold in 1.25 mg/3 mL, 0.63 mg/3 mL and 0.31 mg/3 mL strengths under the Prasco label in the United States.

Sunovion's Xopenex (levalbuterol HCl) is indicated for the treatment or prevention of bronchospasm, or the narrowing of the airways, in patientsa age 6 and older with reversible obstructive airway disease.

"We are especially excited to welcome Sunovion, a leader in treatment of respiratory disorders, to our Prasco family of partners," stated Christopher Arington, chief executive officer of Prasco. "Through this authorized generic, patients currently using Xopenex Inhalation Solution now have options to discuss with their health care professionals of remaining on the branded product or changing to the authorized generic version of Xopenex Inhalation Solution as part of their ongoing treatment regimen."

Advertisement